Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

Natural products can help overcome cancer drug resistance.

Menopausal women have higher androgen levels, which can cause symptoms like facial hair growth and low sexual desire.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

Intralesional therapy for keratoacanthoma is effective and has fewer side effects than systemic treatments.

Soy isoflavones can protect lung tissue from radiation damage.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Steroid sulfatase is important for activating hormones that affect memory, brain function, and certain diseases, and could be a target for treating hormone-related disorders.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Chemotherapy can cause brain inflammation and damage, and understanding this process could help manage side effects.

The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

People undergoing chemotherapy need better support and information to cope with hair loss.

High-dose radiation speeds up aging in skin stem cells.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Sorafenib after liver surgery may increase survival for some liver cancer patients.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

The SA-MS hydrogel is a promising material for improving wound healing and skin regeneration in diseases like diabetes and skin cancer.

Most skin changes during pregnancy are harmless and moles don't significantly change, but many women experience pigmentation changes due to hormones and sun exposure.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

A rare scalp condition causing hair loss and cysts in young men can be treated effectively with a specific steroid injection.

New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Scalp cooling to prevent hair loss from chemotherapy works for some but not all, and studying hair damage markers could improve prevention and treatment.